Clinical trials for Alzheimer disease drugs have an exceptionally high failure rate, discouraging investment in the field despite the unmet medical need. Drug developers need to more effectively harness existing and emerging data and digital technologies to improve the likelihood of success.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Machine learning compensates fold-change method and highlights oxidative phosphorylation in the brain transcriptome of Alzheimer’s disease
Scientific Reports Open Access 01 July 2021
-
Identification of contributing genes of Huntington’s disease by machine learning
BMC Medical Genomics Open Access 23 November 2020
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Cummings, J., Morstorf, T. & Zhong, K. Alzheimer’s disease drug-development pipeline: few candidates, frequent failures. Alzheimers Res. Ther. 6, 37 (2014).
Zhang, R., Simon, G. & Yu, F. Advancing Alzheimer’s research: a review of big data promises. Int. J. Med. Inform. 106, 48–56 (2017).
Khozin, S., Pazdur, R. & Shah, A. INFORMED: an incubator at the US FDA for driving innovations in data science and agile technology. Nat. Rev. Drug Discov. https://doi.org/10.1038/nrd.2018.34 (2018).
Kulmala, J., Ngandu, T. & Kivipelto, M. Prevention matters: time for global action and effective implementation. J. Alzheimers Dis. https://doi.org/10.3233/JAD-179919 (2018).
Bourla, A., Ferreri, F., Ogorzelec, L., Guinchard, C. & Mouchabac, S. Assessment of mood disorders by passive data gathering: the concept of digital phenotype versus psychiatrist’s professional culture. Encephale 44, 168–175 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Related links
AETIONOMY: https://www.aetionomy.eu/en/vision.html
CancerLinQ: https://cancerlinq.org/
EPAD: http://ep-ad.org/
Pragmatic Trials of Managing Multimorbidity in Alzheimer’s Disease: https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-18-028.html
Rights and permissions
About this article
Cite this article
Perakslis, E., Riordan, H., Friedhoff, L. et al. A call for a global ‘bigger’ data approach to Alzheimer disease. Nat Rev Drug Discov 18, 319–320 (2019). https://doi.org/10.1038/nrd.2018.86
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.86
This article is cited by
-
Machine learning compensates fold-change method and highlights oxidative phosphorylation in the brain transcriptome of Alzheimer’s disease
Scientific Reports (2021)
-
Identification of contributing genes of Huntington’s disease by machine learning
BMC Medical Genomics (2020)